The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Swiss pharma giant Novartis AGNVS reported better-than-expected results for the second quarter of 2025 and upped annual guidance for core operating income. Core earnings (excluding one-time charges) ...

In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...

Novartis reported an impressive 11% increase in sales in constant currency, accompanied by a 21% rise in core operating income for Q2 2025. This growth underscores the company’s strong financial ...

Novartis, like all branded pharmaceutical firms, faces a number of threats, including drug trial failures, extended new drug approval times, pricing pressure from the managed-care industry, and ...

Novartis already has some deals in place that could help it reach that target, including an access pact with NHS England aimed at accelerating access to Leqvio after EMA approval.